Kilitch Drugs Quarterly Results for Trading Insights
In Mar 2026, Kilitch Drugs (KILITCH) reported revenue ₹90 Cr and net profit ₹15 Cr — revenue +42.9% YoY. Compare with KILITCH fair value estimate to assess whether the stock is under or overvalued.
KILITCH Quarterly Results — Revenue, Profit & EPS Highlights
Kilitch Drugs latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit KILITCH stock price BSE.
- Revenue of ₹90 Cr in Mar 2026 (+60.7% vs Sept 2025, +42.9% vs Mar 2025)
- Net Profit of ₹15 Cr in Mar 2026 (+87.5% vs Sept 2025, +50.0% vs Mar 2025)
- EBITDA of ₹23 Cr in Mar 2026 (+91.7% vs Sept 2025)
- Operating Margin of 25.0% in Mar 2026 (+15.0pp vs Sept 2025)
- Earnings Per Share of ₹4.24 in Mar 2026 (-14.7% vs Sept 2025)
Kilitch Drugs Quarterly Results — Revenue, EBITDA, Net Profit & EPS
KILITCH quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 90 | 56 | 63 | 46 | 55 | 60.7% | 42.9% |
| Net Profit (₹ Cr) | 15 | 8 | 10 | 2 | 4 | - | - |
| EBITDA (₹ Cr) | 23 | 12 | 16 | 6 | 8 | - | - |
| EPS (₹) | 4.24 | 4.97 | 6.47 | 1.88 | 2.50 | - | - |
| Operating Margin (%) | 25.0% | 10.0% | 24.0% | 8.0% | 11.0% | - | - |
KILITCH Share Price Trend — 1-Year Movement Across Quarterly Results
Kilitch Drugs 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Also explore KILITCH share price history to track price trends across different timeframes.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
KILITCH vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Kilitch Drugs latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2025 |
₹450,643.09 Cr | 1891.3 | 14,875 | 3,125 | +10.8% | - | 21.0% | 145.5 |
|
Divis Laboratories
Sept 2025 |
₹179,470.03 Cr | 6858.0 | 2,860 | 689 | +7.1% | - | 24.1% | 264.1 |
|
Torrent Pharmaceuti…
Sept 2025 |
₹148,702.77 Cr | 4469.2 | 3,219 | 591 | +11.3% | - | 18.4% | 254.8 |
|
Cipla
Mar 2026 |
₹115,205.68 Cr | 1401.9 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 204.1 |
|
Dr Reddys Laborator…
Mar 2026 |
₹111,107.68 Cr | 1318.5 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 497.5 |
All amounts in ₹ Crores